Zaltrap failed the phase-3 VENICE trial in metastatic CRPC, which tested Taxotere ± Zaltrap in the first-line mCRPC setting. The announcement is in the same PR as the immediately preceding post.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.